evipedia.ai
← Back

Apigenin for Health & Longevity

Evidence Review created on 09/06/2026 using AI4L / Opus 5

Also known as: 4’,5,7-trihydroxyflavone, Apigenol, Apigenine, Versulin, Spigenin

Motivation

Apigenin is a plant pigment found in chamomile flowers, parsley, celery and a handful of other common herbs. It has moved from herbal infusion to isolated supplement, sold as a capsule taken in the evening. Two ideas drive the interest: that it calms nerve signalling in the brain, and that it slows the loss of a cellular fuel-handling molecule that falls steadily with age.

Chamomile has been consumed as a calming infusion for centuries, and modern chemistry named apigenin as one of the reasons. The compound is now among the most heavily worked-on plant pigments in the laboratory. Almost all of that work sits in cells and animals rather than people, and only a very small fraction of a swallowed dose survives digestion to reach the bloodstream.

This review examines what is known about apigenin in humans: where the evidence comes from, how firm it is, which benefits and harms have actually been recorded, and how the compound is sourced, dosed and monitored. It keeps findings obtained with isolated apigenin separate from findings obtained with whole plant extracts that happen to contain it.

Benefits - Risks - Protocol - Conclusion

High-level material that explains apigenin’s proposed roles in sleep, ageing biology and disease prevention.

  • Apigenin: a natural molecule at the intersection of sleep and aging - Kramer & Johnson, 2024

    The single best synthesis of the longevity case, tying CD38 inhibition (CD38 is an enzyme that consumes cellular fuel molecules) to sleep effects. Written at Tally Health, a company selling ageing-related products.

  • Do Magnesium, Apigenin, and L-Theanine Improve Sleep? - Rhonda Patrick

    A sceptical walk-through of the popular evening supplement combination, stating plainly that the reported doses are not a recommendation and that the human sleep evidence for each ingredient is thin.

  • How Apigenin May Reduce Senescence and Cancer - Anna Drangowska-Way

    Explains the 2025 screening study that identified apigenin as senomorphic (suppressing the inflammatory output of worn-out cells) rather than senolytic (killing those cells outright), and where that finding stops.

  • Toolkit for Sleep - Andrew Huberman

    Sets out the sleep protocol that made apigenin popular, naming the 50 mg evening dose in context. Useful as the origin of the dose most users copy; the newsletter discloses a supplement-brand affiliation.

  • How Vegetable Extracts Protect Against Cancer - Rita Haven

    A detailed lay account of apigenin’s proposed anticancer, brain and cardiometabolic mechanisms. Published by Life Extension, which sells apigenin-containing formulas, so the framing is promotional.

Two priority sources yielded nothing usable. Peter Attia’s on-site search returns no results for apigenin. Chris Kresser’s site returns only a broad phytochemical overview that names apigenin in passing, without discussing it in any depth, so it was not listed rather than padding the section with marginal material.

Grokipedia

  • Apigenin

    Covers chemistry, plant occurrence, dietary intake and biological effects with inline references, and is useful mainly as a compact orientation to the compound’s chemical identity and food sources.

Examine

  • Apigenin

    Examine’s assessment is blunt: usefulness as a supplement is limited by poor absorption and an absence of human trials, and no dosage range can be given. It also lists the theoretical drug interactions.

ConsumerLab

Systematic Reviews

Systematic reviews and meta-analyses that pool the apigenin literature across disease areas.

The principal trade-off of taking apigenin is exchanging an unproven benefit for unknown long-term risk. No systematic review or meta-analysis of apigenin’s harms exists; the risk side of the ledger is therefore unrepresented in this section and rests on the case reports and mechanistic work cited under Potential Risks & Side Effects.

Mechanism of Action

Apigenin is a flavone with three hydroxyl groups, promiscuous rather than selective, binding several unrelated targets at overlapping concentrations.

  • Nerve signalling. It binds the benzodiazepine site — the docking point used by anti-anxiety drugs such as diazepam — on the GABA-A receptor (GABA is the brain’s main calming messenger), reducing anxiety at low doses and sedating at higher ones in rodents.
  • Cellular fuel. It inhibits CD38, the main consumer of NAD⁺ (nicotinamide adenine dinucleotide, a coenzyme central to energy metabolism that declines with age), raising NAD⁺ and activating sirtuins, a family of repair enzymes.
  • Inflammation. It suppresses NF-κB (a master switch for inflammatory genes) and blocks PRDX6 (peroxiredoxin 6, a redox enzyme), damping the inflammatory secretions of worn-out cells.

A competing reading holds that none of this matters in people: the concentrations producing these effects in cell culture far exceed anything reachable by mouth, so any human benefit must come from a different, lower-concentration mechanism or from apigenin’s metabolites.

Apigenin is poorly soluble and heavily metabolised. Glycosides (sugar-attached forms) in food are cleaved by gut bacteria before absorption; the freed compound is then glucuronidated and sulfated in the gut wall and liver, so plasma levels stay in the nanomolar range. In humans, plasma peaks about seven hours after a food dose and falls below detection within 28 hours, while rodent work shows a long terminal elimination phase and wide tissue distribution, including the brain. It also inhibits cytochrome P450 enzymes (the liver’s main drug-clearing family, including CYP3A4) in the laboratory.

Historical Context & Evolution

Apigenin’s original use was not as a compound at all. Chamomile flowers, its richest common source, were used as a sedative and digestive tea across Europe, North Africa and western Asia for centuries, and the flower’s yellow pigments were also used as a textile dye. Apigenin was isolated and characterised as the flavone responsible for part of chamomile’s activity long before anyone proposed taking it on its own.

The pivot to health optimisation came from two separate laboratory findings. In 1995, apigenin was shown to bind the central benzodiazepine receptor and to produce anxiety-reducing effects in rodents, which gave the traditional tea a receptor-level explanation. In 2013, a Mayo Clinic group identified apigenin as an inhibitor of CD38 and showed that giving it to obese mice raised NAD⁺, reduced protein acetylation and improved glucose and lipid handling. That second finding is what moved apigenin from the herbal-calmative category into the longevity supplement category.

An early human signal has never been resolved either way. A German prospective cohort comparison in patients whose colorectal cancer had been resected reported markedly fewer recurrences in those taking a daily flavonoid mixture containing apigenin. It was small and not randomised, and the confirmatory randomised trial that followed was suspended before completion. The finding has not been refuted; it has simply been left untested, which is a different situation from a claim that failed replication.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: there is no replicated class of human outcome data for apigenin at all — no randomised trial of isolated apigenin has reported a clinical endpoint or a validated clinical surrogate, let alone in more than one trial.

Medium 🟩 🟩

Improved skin density, elasticity and fine wrinkling with topical use

A single randomised human study of an apigenin-containing cream reported increased dermal density and skin elasticity, shorter fine wrinkles, and better skin evenness, moisture and barrier function. The proposed mechanism is suppression of matrix metalloproteinase-1 (MMP-1, the enzyme that breaks down collagen) after ultraviolet exposure. The work was small, ran alongside the authors’ own cell experiments, and involved a company developing the cream, so independent replication is absent. It is also topical, and says nothing about swallowed apigenin. (Choi et al., 2016)

Magnitude: Direction is favourable — dermal density and elasticity rose and fine-wrinkle length fell over the treatment period relative to the identical cream without apigenin; the published report gives no effect-size figure for these skin endpoints.

Low 🟩

Reduced anxiety, with mixed effects on sleep itself ⚠️ Conflicted

Human evidence comes from chamomile extract, not isolated apigenin. Randomised trials in generalised anxiety disorder showed greater symptom reduction than placebo, while a randomised insomnia trial found no change in any sleep-diary measure. Net reading: the calming effect is modest but real; the sleep effect is not established.

Magnitude: Anxiety scores fell 3.17 points further on the Hamilton anxiety scale over 8 weeks on chamomile titrated to at most 1,100 mg daily than on placebo (P = 0.047, where P is the probability a difference this large arose by chance), and stayed lower through 26 weeks of continuation at 1,500 mg daily (P = 0.0032), while sleep latency, total sleep time and night-time awakenings showed no significant difference at 270 mg twice daily. (Amsterdam et al., 2009; Mao et al., 2016; Zick et al., 2011)

Reduced menopausal symptoms with chamomile extract

Evidence again comes from chamomile rather than isolated apigenin. A triple-blind randomised trial in postmenopausal women reported lower total menopausal symptom scores than placebo, with the hot-flush, mood, movement and urinary subscores all falling. Single trial, small, and the extract supplies many compounds besides apigenin.

Magnitude: Total menopausal symptom score fell 10.36 points further on chamomile than on placebo over 12 weeks (P < 0.001), on 100 mg capsules four times daily in 80 postmenopausal women. (Mohsenzadeh-Ledari et al., 2025)

Lower testosterone in polycystic ovary syndrome with chamomile extract ⚠️ Conflicted

Chamomile again, not isolated apigenin. A randomised trial in women with polycystic ovary syndrome (a common hormonal and ovulation disorder) reported lower total testosterone, while a later pooled analysis of three trials found no such effect. Net reading: the hormonal claim is unconfirmed.

Magnitude: Total testosterone fell significantly versus placebo on 370 mg chamomile three times daily for 3 months in 80 women of reproductive age (P = 0.017), while pooling three trials gave no significant testosterone effect; blood fats and the luteinising-to-follicle-stimulating hormone ratio were unchanged in both analyses. (Heidary et al., 2018; Firoozi et al., 2026)

Fewer recurrences of colorectal neoplasia (new growths in the bowel) after resection

In a prospective cohort comparison, patients with resected colorectal cancer who took a daily mixture supplying 20 mg apigenin plus 20 mg epigallocatechin gallate had fewer recurrent cancers or adenomas (benign growths) than matched untreated controls. It was small, non-randomised, and used two components, so apigenin’s own contribution is unknown.

Magnitude: Combined neoplasia recurrence was 7% (1 of 14) on the flavonoid mixture versus 47% (7 of 15) in matched controls over 3–4 years of surveillance colonoscopy (P = 0.027). (Hoensch et al., 2008)

Lower all-cause mortality with a flavonoid-rich diet

Apigenin belongs to the flavone subclass whose dietary intake tracks with survival. In a 23-year Danish cohort of 56,048 adults, flavonoid intake was associated with lower all-cause, cardiovascular and cancer mortality. This is observational, covers total flavonoids from foods, and cannot separate the compound from the diet carrying it.

Magnitude: All-cause death rate was about 17% lower at a median intake of 494 mg total flavonoids per day than at 173 mg per day (hazard ratio 0.83, the ratio of event rates between the two groups); the association plateaued above roughly 500 mg daily and was steeper in smokers and in people drinking more than 20 g alcohol daily. (Bondonno et al., 2019)

Speculative 🟨

Preservation of NAD⁺ through CD38 inhibition

The central longevity claim. Apigenin inhibits CD38, and in obese mice raised NAD⁺, cut protein acetylation and improved glucose and lipid handling. No human study has measured NAD⁺ after apigenin. (Escande et al., 2013)

Suppression of the worn-out-cell secretome

A 2025 natural-product screen found apigenin acts as a senomorphic, blunting inflammatory secretion from senescent cells via PRDX6, and improved frailty in prematurely aged mice. Cells and mice only. (Zhang et al., 2025)

Antitumour activity

Apigenin slows growth, restores programmed cell death and reduces invasion across tumour models. The pooled evidence is explicitly animal and in-vitro; no controlled human cancer trial has been completed. (Singh et al., 2022)

Cognitive protection

Rodent studies report better learning and memory, less amyloid toxicity and reduced brain inflammation. Basis is entirely preclinical, with no human cognitive outcome measured. (Olasehinde & Olaokun, 2024)

Cardiometabolic improvement

Animal work reports lower blood glucose, better lipid handling and improved vessel-lining function. No human trial has measured these endpoints after apigenin. (Xu et al., 2022)

Benefit-Modifying Factors

  • Gut microbiome composition: Most dietary apigenin arrives as glycosides that gut bacteria must cleave before absorption. People with fewer of the bacteria that do this cleaving extract less from parsley, celery or chamomile, though this matters less for purified apigenin capsules.

  • Baseline anxiety and sleep quality: The only human signals came from people with diagnosed anxiety or insomnia. Someone already sleeping and coping well has less measurable room to improve, so the expected effect shrinks toward zero.

  • CD38 activity and baseline NAD⁺: CD38 rises with age and inflammation. The proposed cellular-fuel benefit should be largest in older, inflamed individuals with already-depleted NAD⁺ and negligible in young people with intact levels.

  • Genetic variation in conjugating enzymes: Apigenin is cleared by UGT and SULT enzymes (which attach sugar or sulfate groups to speed excretion). Common low-activity variants plausibly raise free plasma levels, but no study has tested this in people.

  • Sex: No sex-stratified human apigenin data exist. Laboratory work showing effects on oestrogen- and androgen-producing enzymes makes differing responses plausible in either direction, so this remains an open question rather than a known modifier.

  • Pre-existing conditions: Liver disease slows conjugation and raises exposure; inflammatory bowel disease alters the flora needed to release apigenin from food glycosides.

  • Age: Older adults carry the higher CD38 burden the longevity rationale targets, but also more polypharmacy and slower drug clearance, which raises the interaction risk described below.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse-event class has been documented for isolated apigenin in more than one trial, because no completed randomised trial of isolated oral apigenin has published an adverse-event table.

Medium 🟥 🟥

No risk reaches Medium: no single controlled trial or consistent observational dataset records a harm attributable to apigenin itself; the human safety record consists of case reports and of adverse-event counts from trials of whole chamomile extract.

Low 🟥

Allergic reactions, including anaphylaxis, to chamomile-derived preparations

Most apigenin supplements are chamomile extracts. Chamomile cross-reacts with mugwort and ragweed pollen, and published cases run from hives to anaphylaxis (a whole-body allergic reaction), including one death after a chamomile enema. Sensitisation is to daisy-family proteins rather than apigenin, so purified apigenin products should not carry it.

Magnitude: Risk is concentrated in people already sensitised to mugwort or ragweed pollen and rises with mucosal rather than oral exposure; the literature consists of case series and single reports and gives no incidence figure. (Reider et al., 2000; Jensen-Jarolim et al., 1998)

Falling body weight and blood pressure on prolonged use

The 26-week chamomile continuation trial found significant reductions in body weight and mean arterial pressure alongside the anxiety benefit. In an already-lean or already-hypotensive user, both are unwanted, and neither is usually looked for. The finding comes from whole extract, so apigenin’s contribution is unknown.

Magnitude: Both fell significantly versus placebo over 26 weeks at 1,500 mg chamomile extract daily (body weight P = 0.046; mean arterial pressure P = 0.0063); the report gives significance values without absolute change figures. (Mao et al., 2016)

Sedation carried into the following day

Sedation is the intended effect at bedtime and the unwanted one at 8 a.m. Rodent work shows apigenin is anxiety-reducing at low doses and frankly sedative at high ones, so the margin is dose-dependent. The two controlled chamomile trials recorded adverse-event rates no different from placebo.

Magnitude: Direction is dose-dependent, with sedation appearing above anxiety-reducing doses in animals; the human trials report only that overall adverse-event rates did not differ from placebo and give no incidence figure for daytime sedation. (Amsterdam et al., 2009; Mao et al., 2016)

Speculative 🟨

Raised blood levels of co-administered medicines

Apigenin raised venlafaxine and dasatinib exposure in rats by inhibiting drug-clearing enzymes and transporters, and slowed venlafaxine breakdown in human liver preparations. No human data exist. (Zhan et al., 2015; Raish et al., 2023)

Altered sex-hormone synthesis ⚠️ Conflicted

One study found apigenin inhibits human androgen-synthesising enzymes; another found it increases steroid output in mouse testis cells. Net reading: the direction of effect is unresolved. (Wang et al., 2016; Li et al., 2011)

Interference with thyroid hormone coupling

Vitexin, an apigenin glycoside from millet, inhibited thyroid hormone coupling in rats at high doses without reducing iodine uptake. The tested compound was the glycoside, not apigenin. (Gaitan et al., 1995)

Impaired platelet aggregation

Apigenin blocked platelet aggregation by up to 97% in cell culture, but only at concentrations unreachable by mouth. Feeding volunteers 84 mg apigenin daily changed no clotting variable. (Janssen et al., 1998)

Risk-Modifying Factors

  • Daisy-family pollen sensitisation: Established allergy to mugwort, ragweed, feverfew or chrysanthemum is the single strongest predictor of a reaction to chamomile-sourced apigenin, and is irrelevant to purified apigenin products.

  • Baseline blood pressure and body weight: A lean user with mean arterial pressure already at the low end has the least headroom for the reductions seen over 26 weeks of chamomile, and the most to lose from them.

  • Baseline thyroid status: Existing hypothyroidism or borderline thyroid-stimulating hormone leaves less reserve if the flavone effect on hormone coupling seen in rodents translates at all.

  • Sex: Effects on androgen- and oestrogen-handling enzymes run in opposite directions between studies, so both sexes carry an unresolved hormonal question; women on aromatase inhibitors (oestrogen-blocking drugs) and men on testosterone therapy have most at stake.

  • Genetic variation in conjugating enzymes: Low-activity UGT and SULT variants would raise and prolong free apigenin exposure, plausibly amplifying every interaction risk below, but no study has genotyped anyone taking apigenin, so the effect is unquantified.

  • Polypharmacy and narrow-therapeutic-index drugs: Anyone on a medicine where small exposure changes matter carries most of apigenin’s realistic risk, given its laboratory effects on drug-clearing enzymes and transporters.

  • Liver or kidney impairment: Both slow conjugation and excretion of apigenin, raising and prolonging exposure with no human data to guide adjustment.

  • Age: Older adults combine more medicines, slower clearance and thinner physiological reserve, which magnifies every interaction concern above.

Key Interactions & Contraindications

  • Sedatives and central nervous system depressants (benzodiazepines, Z-drugs such as zolpidem, opioids, gabapentinoids such as pregabalin, alcohol): Caution. Additive sedation and impaired next-day alertness, given apigenin’s benzodiazepine-site binding. The reported concern is combining it before driving or an early duty start.

  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin): Caution. Theoretical additive bleeding risk. Human feeding data showed no clotting change, but chamomile products warrant an extra INR (international normalised ratio, a clotting-time measure) check after starting.

  • Narrow-therapeutic-index substrates of CYP3A4 and P-glycoprotein (a pump that expels drugs from cells) (tacrolimus, ciclosporin, dasatinib, some statins): Caution to avoid. Raised drug exposure and toxicity. Separate dosing does not reliably help; the mitigations described are drug-level monitoring or non-use.

  • Serotonergic antidepressants cleared hepatically (venlafaxine, sertraline): Caution. Raised antidepressant levels with more nausea, sweating and blood-pressure rise. Prompt reporting of new side effects, rather than antidepressant dose adjustment, is the described mitigation.

  • Losartan and other medicines the liver must activate: Caution. Altered conversion could blunt or exaggerate the blood-pressure effect. Home blood-pressure monitoring for two weeks after starting is the usual mitigation.

  • Over-the-counter sedating antihistamines (diphenhydramine, doxylamine) and melatonin: Caution. Additive sedation and impaired next-morning alertness. Using a single evening sedative rather than combining them is the described mitigation.

  • Non-steroidal anti-inflammatory drugs: Monitor. No documented pharmacokinetic clash, but the combined theoretical platelet effect adds to bruising risk in heavy users.

  • Supplements with additive sedation (valerian, passionflower, magnesium, L-Theanine, glycine, kava): Caution. These are the usual co-administered agents; each adds sedative load, which is why staggered single-agent introduction is the described approach.

  • Supplements with additive antiplatelet effect (fish oil, ginkgo, garlic, high-dose vitamin E, quercetin): Monitor. Quercetin also inhibits CD38, so the combination doubles down on the same mechanism without added evidence.

  • Other interventions (nicotinamide riboside, nicotinamide mononucleotide): Monitor. Pairing a cellular-fuel precursor with apigenin, which blocks that molecule’s breakdown, has been tested only in mice; the combined effect in people, beneficial or otherwise, is unknown.

Populations who should avoid Apigenin:

  • Pregnant and breastfeeding women — safety data are absent, and avoidance is the position of the reference sources.
  • People with documented chamomile or daisy-family allergy, including mugwort or ragweed cross-sensitisation, when the product is chamomile-derived.
  • Solid-organ transplant recipients on anti-rejection medicines such as tacrolimus or ciclosporin, where a shift in drug exposure risks rejection or toxicity.
  • People with hormone-receptor-positive breast or prostate cancer on endocrine therapy (oestrogen- or testosterone-blocking drugs), given unresolved effects on steroid-synthesising enzymes.
  • People with Child-Pugh Class B or C liver impairment (a severity grading for chronic liver disease), in whom conjugation capacity is materially reduced.
  • Anyone within two weeks of scheduled surgery, following the standard supplement washout for agents with theoretical platelet effects.

Risk Mitigation Strategies

  • Low starting dose held for two weeks: Protocols begin at 50 mg in the evening, the dose used in the sepsis pilot trial, and hold there for two weeks. This limits daytime sedation and surfaces idiosyncratic reactions early.

  • Bedtime-only dosing: Dosing 30–60 minutes before sleep keeps the sedative effect where it is wanted and reduces the chance of impaired alertness during the working day; morning dosing does the opposite.

  • Purified apigenin in place of chamomile extract: Choosing a purified apigenin product over a chamomile extract removes the daisy-family proteins responsible for every published anaphylaxis case, which is the only documented serious harm.

  • Staggered introduction of sedative supplements: Adding apigenin to an existing regimen of magnesium, theanine or valerian separately, two weeks apart, makes it possible to attribute both benefit and residual sedation correctly.

  • Monthly blood-pressure and weight checks: Home readings and a monthly weight catch the falls in mean arterial pressure and body weight seen over 26 weeks of chamomile, which are unwanted in a lean user.

  • Coordination around narrow-therapeutic-index medicines: For anyone on tacrolimus, ciclosporin, warfarin or a targeted cancer drug, the described options are a drug-level or INR check 2–4 weeks after starting, or non-use.

  • Two-week washout before surgery or dental extraction: A 14-day washout removes the theoretical additive platelet effect ahead of any procedure with bleeding risk.

  • Three-month reassessment point: If no change in sleep onset, anxiety or daytime function is apparent by 12 weeks, discontinuing avoids indefinite exposure to an unproven agent.

Therapeutic Protocol

  • Standard dose: 50 mg of apigenin once daily is the dose used in essentially all consumer protocols and matches the 50 mg tablet used in the completed sepsis pilot trial. No dose-ranging study in healthy adults exists.

  • Timing: Taken 30–60 minutes before bed. This is universal across practitioner and popular protocols and follows from the sedative rather than the metabolic rationale.

  • Competing approach — food first: An alternative position, taken by Examine and by ConsumerLab, is that apigenin is adequately obtained from parsley, celery and chamomile tea, and that supplementation adds cost without evidence.

  • Competing approach — precursor pairing: A second position pairs apigenin with a cellular-fuel precursor on the theory that blocking breakdown complements supply. This rests on mouse work and is neither more nor less proven than the single-agent approach.

  • Who popularised each: The evening 50 mg dose was popularised through Andrew Huberman’s sleep toolkit; the metabolic rationale traces to the Mayo Clinic group that identified CD38 inhibition.

  • Half-life: Plasma apigenin peaks around seven hours after a food dose and falls below detection within 28 hours, while rodent data show a long terminal phase; a single evening dose is consistent with both.

  • Single versus split dosing: Single evening dosing is standard. Splitting undermines the only rationale with human support, since a daytime dose delivers sedation when it is not wanted.

  • Genetic considerations: No pharmacogenetic guidance exists. Variants in the UGT and SULT conjugating enzymes plausibly alter exposure, but no study has genotyped apigenin users, so no dose adjustment can be justified.

  • Sex-based differences: No sex-specific dosing exists. Given unresolved laboratory effects on hormone-synthesising enzymes, women on endocrine therapy and men monitoring testosterone have most reason to track hormones.

  • Age: Older adults are the group the metabolic rationale targets and also the group with slowest clearance and most co-medication; the same 50 mg with closer interaction review is the pragmatic compromise.

  • Baseline biomarkers: Nothing predicts response. Practitioners who use it at all track subjective sleep and anxiety plus a general inflammation marker rather than any apigenin-specific test.

  • Pre-existing conditions: Liver impairment, inflammatory bowel disease and existing sedative use each argue for the lowest dose or for not starting; none has been studied directly.

Discontinuation & Cycling

  • Lifelong or short-term: No evidence supports either. The sedative use is naturally as-needed and short-term; the longevity rationale implies indefinite use that no human study has ever evaluated for safety or benefit.

  • Withdrawal effects: None documented. No trial has reported rebound anxiety or insomnia after stopping apigenin or chamomile, though no trial has specifically looked for them either.

  • Tapering: Not required by any published protocol. Abrupt discontinuation is what happened in the placebo-substitution phase of the chamomile trial without a withdrawal syndrome being described.

  • Cycling for efficacy: No tolerance to apigenin has been demonstrated, so there is no evidence-based reason to cycle. Some users cycle four nights on, three off, which is a habit rather than a finding.

  • A practical reason to pause: Stopping for two weeks and observing whether sleep or anxiety worsens is the only way an individual can test whether the compound is doing anything, given the absence of trial data.

Sourcing and Quality

  • Purified compound versus plant extract: Products supply either purified apigenin (the aglycone, or sugar-free form) or a chamomile or parsley extract standardised to apigenin content. Extracts carry the allergy risk; the purified form carries the stability problem. Labels frequently omit which is inside.

  • Stability is the core problem: Isolated apigenin is unstable and poorly soluble. Examine’s guidance is to favour manufacturers who address this in formulation rather than selling bare powder that degrades on the shelf.

  • Bioavailability-enhancing formulations: Self-nanoemulsifying systems, liposomes, phospholipid complexes and solid dispersions all raise absorption in preclinical work. None has been shown to change a human outcome, so they buy plausibility, not proof.

  • Third-party testing: The relevant marks are NSF Certified for Sport, Informed Choice and United States Pharmacopeia verification, or at minimum a batch certificate of analysis reporting apigenin content by chromatography plus heavy-metal and microbial screens.

  • Brands and suppliers: Life Extension, Swanson, Double Wood, Nootropics Depot and Momentous all sell apigenin; Life Extension and Momentous also publish or sponsor the educational content promoting it, which is a direct commercial interest.

  • Food sources as an alternative: Dried parsley, celery, chamomile tea, artichoke and kumquat all supply apigenin. Typical dietary intake is roughly 0.45–5 mg daily, an order of magnitude below a 50 mg capsule.

Practical Considerations

  • Time to effect: The sedative effect, if present, is felt the first night, within 30–60 minutes. Any metabolic or ageing-related effect has no established timeline because no human study has measured one.

  • Common pitfall — expecting the mouse result: The NAD⁺ and senescence findings come from doses and tissue concentrations far above what a 50 mg oral capsule produces in a person. Translating them directly is the central error.

  • Common pitfall — combining agents blindly: Apigenin is usually added to magnesium, theanine and glycine at once, making it impossible to know which ingredient, if any, is responsible for a change in sleep.

  • Common pitfall — ignoring the source plant: Users with seasonal allergic rhinitis routinely take chamomile-derived apigenin without realising it carries the allergy risk that purified aglycone does not.

  • Regulatory status: Sold as a dietary supplement in the United States and as a food supplement in the European Union. It is not an approved medicine anywhere, carries no prescribing information, and is not on the 2026 World Anti-Doping Agency prohibited list.

  • Cost and accessibility: Widely available and inexpensive, typically a few cents per 50 mg dose. Cost is not a barrier, which is also why no manufacturer has funded a definitive trial.

Interaction with Foundational Habits

  • Sleep: Potentiating and direct. Evening dosing is the point, and the benzodiazepine-site mechanism is plausible, but the one randomised insomnia trial of chamomile found no change in sleep latency, total sleep time or awakenings. A defined 12-week trial period with a stop point, and separation from alcohol, is the framing the evidence supports.

  • Nutrition: Direct and mostly favourable. Apigenin is absorbed better with a fat-containing meal given its poor water solubility, and gut bacteria must cleave the glycosides in parsley, celery and chamomile before absorption. A fibre-rich diet that supports those bacteria therefore raises what food delivers. No nutrient depletion has been reported.

  • Exercise: Indirect, with a theoretical caution. No human trial has tested apigenin around training. Because part of the training adaptation signal runs through transient inflammation and oxidative stress, a strong anti-inflammatory taken immediately post-workout is a theoretical blunting risk; evening dosing keeps it far from the session.

  • Stress management: Potentiating and indirect. The anxiety reduction seen with chamomile extract complements rather than replaces breathing practice, daylight exposure and cognitive behavioural therapy for insomnia, which have much stronger evidence. An exploratory chamomile study also examined salivary cortisol, without establishing a stress-hormone effect.

Monitoring Protocol & Defining Success

Baseline assessment before starting apigenin covers a two-week record of sleep onset, night-time awakenings and morning alertness, plus resting blood pressure, body weight and a short anxiety self-rating. The fasting panel covers inflammation, glucose handling, liver enzymes and thyroid function, with sex hormones added only where endocrine therapy or a hormone-sensitive condition applies. No apigenin-specific blood test exists, so every marker below is a safety or general-health check rather than a measure of effect.

Ongoing monitoring is monthly home blood pressure and weight, with the blood panel repeated at 12 weeks and then every 6–12 months if use continues. For a narrow-therapeutic-index medicine, that drug’s level or clotting time is checked 2–4 weeks after starting and after any dose change.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
hs-CRP Below 1.0 mg/L Tracks the general inflammation the anti-inflammatory rationale targets hs-CRP is high-sensitivity C-reactive protein, a marker of body-wide inflammation; conventional labs flag only above 3.0 mg/L; testing is deferred for 2 weeks after any infection or hard training block
Fasting insulin 2–5 µIU/mL Earliest signal of the glucose-handling effect claimed from animal work Conventional range runs to 25 µIU/mL; requires an 8–12 hour fast; best paired with fasting glucose
HbA1c 5.0–5.4% Confirms or refutes any sustained glucose effect HbA1c is glycated haemoglobin, roughly a three-month average of blood sugar; conventional cut-off is below 5.7%; unreliable in anaemia or after recent blood loss
ALT 10–19 U/L in women, 10–26 U/L in men Safety check on a heavily liver-metabolised compound ALT is alanine aminotransferase, a liver enzyme; conventional upper limits near 40 U/L are far looser; drawn alongside AST (aspartate aminotransferase) and gamma-glutamyl transferase
TSH 0.5–2.0 mIU/L Safety check against the flavone effect on thyroid hormone coupling seen in rodents TSH is thyroid-stimulating hormone, the pituitary signal that drives the thyroid; conventional range extends to 4.5 mIU/L; drawn before 10 a.m. and paired with free T4 and free T3, the circulating thyroid hormones
Total testosterone (men) or oestradiol (women) No established apigenin-specific target; the marker tracked instead is change from the individual’s own baseline Watches the unresolved effect on steroid-synthesising enzymes Morning draw for men; day 3 of the cycle for premenopausal women; only warranted if endocrine therapy or a hormone-sensitive condition is present
Platelet count and, if anticoagulated, INR Platelets 150–400 ×10⁹/L; INR within the target set for the indication Safety check on the theoretical platelet effect Only needed for people on anticoagulants or antiplatelets, or before surgery; no fasting required

Qualitative markers matter more than any laboratory value here:

  • Time to fall asleep, judged over a week rather than a single night
  • Number of remembered night-time awakenings
  • Morning alertness and absence of residual sedation in the first waking hour
  • Daytime anxiety and rumination, ideally with a repeated short self-rating scale
  • Dream intensity, which some users report changes when apigenin is combined with theanine
  • Overall energy and cognitive clarity through the afternoon

Success is a reproducible improvement in at least one of these that fades on a two-week withdrawal and returns on restarting.

Emerging Research

  • Sepsis organ-function pilot: NCT05999682 randomised 20 patients aged 65 and over to apigenin 50 mg or placebo for four days, with the organ-failure score at 96 hours as the primary endpoint. Completed January 2024; results not yet posted. The first controlled clinical test of isolated apigenin.

  • Absorption and excretion in healthy adults: NCT03526081 at the University of California, Davis followed apigenin and its glycosides through 17 healthy volunteers. This is the class of study most likely to weaken the case, by confirming how little reaches circulation.

  • Colorectal recurrence prevention: NCT00609310, a 382-participant phase 2 trial of bioflavonoid supplementation against neoplasia recurrence after colorectal surgery, is suspended. Its completion would settle the strongest human signal apigenin has.

  • Long COVID inflammation: NCT07397910 will randomise 40 adults with persistent post-viral symptoms to a supplement containing apigenin and luteolin, with or without structured exercise, over four months.

  • Bone-graft scaffold: NCT07678749 is enrolling 22 patients to compare sinus-lift grafting with and without a liposomal apigenin scaffold, an example of the delivery-system work meant to bypass poor oral absorption.

  • Senescence as the next testable claim: Zhang et al., 2025 identified apigenin as a senomorphic acting through PRDX6 and improved frailty in prematurely aged mice. Whether that survives translation to human tissue concentrations is the decisive open question.

  • Formulation as the rate-limiting step: Sato et al., 2024 raised oral apigenin absorption substantially with a self-nanoemulsifying system. Any future positive human trial will most likely use such a vehicle rather than plain powder.

  • The funding gap: Apigenin is unpatentable and costs pennies per dose, so no manufacturer and no insurer has a financial reason to fund a definitive trial. This, rather than negative results, is why the human evidence base remains empty.

Conclusion

Apigenin is a plant compound from chamomile, parsley and celery, sold as an evening capsule on two distinct promises: that it calms the nervous system, and that it protects a cellular fuel molecule that falls with age. The gap between those promises and the human record is wide. No study of purified apigenin has yet reported a health outcome in people. Everything encouraging comes from cells, from animals, or from whole chamomile extract, which contains many other active substances.

What human evidence exists points to modest anxiety relief from chamomile rather than to better sleep, to fewer menopausal complaints on the same herb, to an unconfirmed hormonal shift in women with a common ovulation disorder, and to one small early finding of fewer bowel-tumour recurrences that was never confirmed. The known harms are equally thin: allergic reactions traced to the chamomile plant rather than the compound, quiet reductions in weight and blood pressure over months, and laboratory signals that it could raise the levels of medicines cleared by the liver.

The evidence base is shaped as much by economics as by biology. The compound is cheap and unpatentable, so nobody has a commercial reason to test it properly, while much of the enthusiastic material circulating about it is published by companies that sell it. For someone already optimising sleep and metabolic health, apigenin sits in the category of low-cost, low-signal, largely untested — plausible, inexpensive, and unproven in either direction.

Top - Benefits - Risks - Protocol